Genetic disorders coupled to ROS deficiency

Redox Biology

Volumn 6, Issue , 2015, Pages 135-156

  O'Neill, Sharon ^a   Brault, Julie ^b,c   Stasia, Marie Jose ^b,c   Knaus, Ulla G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic granulomatous disease; DUOX; Genetic disease; Hypothyroidism; Inflammatory bowel disease; NADPH oxidase; NOX; Reactive oxygen species (ROS)

Indexed keywords

INTERLEUKIN 1; IODIDE PEROXIDASE; LACTOPEROXIDASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MYELOPEROXIDASE; PENDRIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE DISMUTASE; THYROGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR; TOLL LIKE RECEPTOR; ZINC FINGER NUCLEASE; CYBB PROTEIN, HUMAN; DUOX2 PROTEIN, HUMAN; DUOXA2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NOX1 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; AUTOPHAGY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHRONIC GRANULOMATOUS DISEASE; COGNITIVE DEFECT; CONGENITAL HYPOTHYROIDISM; CRYSTAL STRUCTURE; CYBA GENE; CYBB GENE; DIMERIZATION; DISEASE COURSE; DOWN REGULATION; EMBRYOID BODY; EPIGENETICS; EXON; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; INTRON; LONG TERM POTENTIATION; MACROPHAGE; NCF1 GENE; NCF2 GENE; NCF4 GENE; NEUTROPHIL; NONHUMAN; NONSENSE MUTATION; OXIDATIVE STRESS; PHAGOCYTOSIS; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PSEUDOGENE; RETINA DETACHMENT; REVIEW; RISK FACTOR; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UPREGULATION; WILLIAMS BEUREN SYNDROME; CARDIOVASCULAR DISEASE; DEFICIENCY; DIABETES MELLITUS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PATHOLOGY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GENE EXPRESSION; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; HYPOTHYROIDISM; INFLAMMATORY BOWEL DISEASES; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MUTATION; NADPH OXIDASE; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84937775382     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.07.009     Document Type: Review

References (247)

1. Moreno M.U., San Jose G., Fortuno A., et al. A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. J. Hypertens. 2007, 25:1620-1626.
2. Moreno M.U., San Jose G., Orbe J., et al. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett. 2003, 542:27-31.
3. Qin Y.W., Peng J., Liang B.Y., et al. The A930G polymorphism ofP22phox (CYBA) gene but not C242T variation is associated with hypertension: a meta-analysis. PLoS ONE 2013, 8:e82465.
4. Moreno M.U., Zalba G. CYBA gene variants as biomarkers for coronary artery disease. Drug News Perspect. 2010, 23:316-324.
5. van den Berg J.M., van Koppen E., Ahlin A., et al. Chronic granulomatous disease: the European experience. PLoS ONE 2009, 4:e5234.
6. Holland S.M. Chronic granulomatous disease. Hematol. Oncol. Clin. N. Am. 2013, 27:89-99.
7. Segal A.W., Jones O.T., Webster D., et al. Absence of a newly described cytochrome b from neutrophils of patients with chronic granulomatous disease. Lancet 1978, 2:446-449.
8. Segal A.W., Cross A.R., Garcia R.C., et al. Absence of cytochrome b-245 in chronic granulomatous disease. A multicenter European evaluation of its incidence and relevance. N. Engl. J. Med. 1983, 308:245-251.
9. Ohno Y., Buescher E.S., Roberts R., et al. Reevaluation of cytochrome b and flavin adenine dinucleotide in neutrophils from patients with chronic granulomatous disease and description of a family with probable autosomal recessive inheritance of cytochrome b deficiency. Blood 1986, 67:1132-1138.
10. Roos D., Kuhns D.B., Maddalena A., et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol. Dis. 2010, 45:246-265.
11. Roos D., Kuhns D.B., Maddalena A., et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol. Dis. 2010, 44:291-299.
12. Matute J.D., Arias A.A., Wright N.A., et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009, 114:3309-3315.
13. Knaus U.G., Heyworth P.G., Evans T., et al. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 1991, 254:1512-1515.
14. Abo A., Boyhan A., West I., et al. Reconstitution of neutrophil NADPH oxidase activity in the cell-free system by four components: p67-phox, p47-phox, p21rac1, and cytochrome b-245. J. Biol. Chem. 1992, 267:16767-16770.
15. Ambruso D.R., Knall C., Abell A.N., et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc. Natl. Acad. Sci. USA 2000, 97:4654-4659.
16. Williams D.A., Tao W., Yang F., et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 2000, 96:1646-1654.
17. Rieber N., Hector A., Kuijpers T., et al. Current concepts of hyperinflammation in chronic granulomatous disease. Clin. Dev. Immunol. 2012, 2012:252460.
18. Brown J.R., Goldblatt D., Buddle J., et al. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J. Leukoc. Biol. 2003, 73:591-599.
19. Bylund J., MacDonald K.L., Brown K.L., et al. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur. J. Immunol. 2007, 37:1087-1096.
20. Brown K.L., Bylund J., MacDonald K.L., et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin. Immunol. 2008, 129:90-102.
21. Bjorkman L., Dahlgren C., Karlsson A., et al. Phagocyte-derived reactive oxygen species as suppressors of inflammatory disease. Arthritis Rheum. 2008, 58:2931-2935.
22. Hartl D., Lehmann N., Hoffmann F., et al. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J. Allergy Clin. Immunol. 2008, 121(375-382):e9.
23. Harden J.L., Egilmez N.K. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Investig. 2012, 41:738-764.
24. Johnson T.S., Munn D.H. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol. Investig. 2012, 41:765-797.
25. Prendergast G.C., Smith C., Thomas S., et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 2014, 63:721-735.
26. Romani L., Fallarino F., De Luca A., et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008, 451:211-215.
27. Jurgens B., Fuchs D., Reichenbach J., et al. Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. Clin. Immunol. 2010, 137:1-4.
28. De Ravin S.S., Zarember K.A., Long-Priel D., et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood 2010, 116:1755-1760.
29. Kurnasov O., Jablonski L., Polanuyer B., et al. Aerobic tryptophan degradation pathway in bacteria: novel kynurenine formamidase. FEMS Microbiol. Lett. 2003, 227:219-227.
30. Farrow J.M., Pesci E.C. Two distinct pathways supply anthranilate as a precursor of the Pseudomonas quinolone signal. J. Bacteriol. 2007, 189:3425-3433.
31. Chugani S., Greenberg E.P. LuxR homolog-independent gene regulation by acyl-homoserine lactones in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 2010, 107:10673-10678.
32. Genestet C., Le Gouellec A., Chaker H., et al. Scavenging of reactive oxygen species by tryptophan metabolites helps Pseudomonas aeruginosa escape neutrophil killing. Free Radic. Biol. Med. 2014, 73:400-410.
33. Levine B., Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat. Rev. Immunol. 2007, 7:767-777.
34. Orvedahl A., Levine B. Eating the enemy within: autophagy in infectious diseases. Cell Death Differ. 2009, 16:57-69.
35. Sanjuan M.A., Dillon C.P., Tait S.W., et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 2007, 450:1253-1257.
36. Huang J., Canadien V., Lam G.Y., et al. Activation of antibacterial autophagy by NADPH oxidases. Proc. Natl. Acad. Sci. USA 2009, 106:6226-6231.
37. van de Veerdonk F.L., Smeekens S.P., Joosten L.A., et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 2010, 107:3030-3033.
38. de Luca A., Smeekens S.P., Casagrande A., et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc. Natl. Acad. Sci. USA 2014, 111:3526-3531.
39. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
40. Lassegue B., San Martin A., Griendling K.K. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res. 2012, 110:1364-1390.
41. Jung O., Schreiber J.G., Geiger H., et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004, 109:1795-1801.
42. Matsuno K., Yamada H., Iwata K., et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112:2677-2685.
43. Violi F., Sanguigni V., Carnevale R., et al. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009, 120:1616-1622.
44. Krotz F., Sohn H.Y., Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100:917-924.
45. Violi F., Pignatelli P. Platelet NOX, a novel target for anti-thrombotic treatment. Thromb. Haemost. 2014, 111:817-823.
46. Nayernia Z., Jaquet V., Krause K.H. New insights on NOX enzymes in the central nervous system. Antioxid. Redox Signal. 2014, 20:2815-2837.
47. Kishida K.T., Hoeffer C.A., Hu D., et al. Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol. Cell. Biol. 2006, 26:5908-5920.
48. Kishida K.T., Pao M., Holland S.M., et al. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J. Neurochem. 2005, 94:299-306.
49. Pao M., Wiggs E.A., Anastacio M.M., et al. Cognitive function in patients with chronic granulomatous disease: a preliminary report. Psychosomatics 2004, 45:230-234.
50. Cole T.S., McKendrick F., Cant A.J., et al. Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. Neuropediatrics 2013, 44:230-232.
51. Fischer M.T., Sharma R., Lim J.L., et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135:886-899.
52. Wu L.J. Microglial voltage-gated proton channel Hv1 in ischemic stroke. Transl. Stroke Res. 2014, 5:99-108.
53. Wu D.C., Re D.B., Nagai M., et al. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc. Natl. Acad. Sci. USA 2006, 103:12132-12137.
54. Leiding J.W., Marciano B.E., Zerbe C.S., et al. Diabetes, renal and cardiovascular disease in p47 phox-/- chronic granulomatous disease. J. Clin. Immunol. 2013, 33:725-730.
55. Kuhns D.B., Alvord W.G., Heller T., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 2010, 363:2600-2610.
56. Biberstine-Kinkade K.J., Yu L., Dinauer M.C. Mutagenesis of an arginine- and lysine-rich domain in the gp91(phox) subunit of the phagocyte NADPH-oxidase flavocytochrome b558. J. Biol. Chem. 1999, 274:10451-10457.
57. Li X.J., Grunwald D., Mathieu J., et al. Crucial role of two potential cytosolic regions of Nox2, 191TSSTKTIRRS200 and 484DESQANHFAVHHDEEKD500, on NADPH oxidase activation. J. Biol. Chem. 2005, 280:14962-14973.
58. Carrichon L., Picciocchi A., Debeurme F., et al. Characterization of superoxide overproduction by the d-Loop(Nox4)-Nox2 cytochrome b(558) in phagocytes - differential sensitivity to calcium and phosphorylation events. Biochim. Biophys. Acta 2011, 1808:78-90.
59. von Lohneysen K., Noack D., Hayes P., et al. Constitutive NADPH oxidase 4 activity resides in the composition of the B-loop and the penultimate C terminus. J. Biol. Chem. 2012, 287:8737-8745.
60. Taylor W.R., Jones D.T., Segal A.W. A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain. Protein Sci. 1993, 2:1675-1685.
61. Tucker K.A., Lilly M.B., Heck L., et al. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 1987, 70:372-378.
62. Zhen L., King A.A., Xiao Y., et al. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc. Natl. Acad. Sci. USA 1993, 90:9832-9836.
63. Yu L., Cross A.R., Zhen L., et al. Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. Blood 1999, 94:2497-2504.
64. Bionda C., Li X.J., van Bruggen R., et al. Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells. Hum. Genet. 2004, 115:418-427.
65. Li X.J., Fieschi F., Paclet M.H., et al. Leu505 of Nox2 is crucial for optimal p67phox-dependent activation of the flavocytochrome b558 during phagocytic NADPH oxidase assembly. J. Leukoc. Biol. 2007, 81:238-249.
66. Debeurme F., Picciocchi A., Dagher M.C., et al. Regulation of NADPH oxidase activity in phagocytes: relationship between FAD/NADPH binding and oxidase complex assembly. J Biol Chem 2010, 285:33197-33208.
67. Picciocchi A., Debeurme F., Beaumel S., et al. Role of putative second transmembrane region of Nox2 protein in the structural stability and electron transfer of the phagocytic NADPH oxidase. J. Biol. Chem. 2011, 286:28357-28369.
68. Raad H., Paclet M.H., Boussetta T., et al. Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J. 2009, 23:1011-1022.
69. Jackson H.M., Kawahara T., Nisimoto Y., et al. Nox4 B-loop creates an interface between the transmembrane and dehydrogenase domains. J. Biol. Chem. 2010, 285:10281-10290.
70. Wallach T.M., Segal A.W. Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro. Biochem. J. 1997, 321(Pt 3):583-585.
71. Yu L., Zhen L., Dinauer M.C. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J. Biol. Chem. 1997, 272:27288-27294.
72. Yu L., Quinn M.T., Cross A.R., et al. Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. Proc. Natl. Acad. Sci. USA 1998, 95:7993-7998.
73. Yu L., DeLeo F.R., Biberstine-Kinkade K.J., et al. Biosynthesis of flavocytochrome b558. gp91(phox) is synthesized as a 65-kDa precursor (p65) in the endoplasmic reticulum. J. Biol. Chem. 1999, 274:4364-4369.
74. von Lohneysen K., Noack D., Wood M.R., et al. Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. Mol. Cell. Biol. 2010, 30:961-975.
75. Kawahara T., Ritsick D., Cheng G., et al. Point mutations in the proline-rich region of p22phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation. J. Biol. Chem. 2005, 280:31859-31869.
76. Zhu Y., Marchal C.C., Casbon A.J., et al. Deletion mutagenesis of p22phox subunit of flavocytochrome b558: identification of regions critical for gp91phox maturation and NADPH oxidase activity. J. Biol. Chem. 2006, 281:30336-30346.
77. von Lohneysen K., Noack D., Jesaitis A.J., et al. Mutational analysis reveals distinct features of the Nox4-p22 phox complex. J. Biol. Chem. 2008, 283:35273-35282.
78. Beaumel S., Grunwald D., Fieschi F., et al. Identification of NOX2 regions for normal biosynthesis of cytochrome b558 in phagocytes highlighting essential residues for p22phox binding. Biochem. J. 2014, 464:425-437.
79. Noack D., Rae J., Cross A.R., et al. Autosomal recessive chronic granulomatous disease caused by defects in NCF-1, the gene encoding the phagocyte p47-phox: mutations not arising in the NCF-1 pseudogenes. Blood 2001, 97:305-311.
80. Roos D., de Boer M., Koker M.Y., et al. Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase. Hum. Mutat. 2006, 27:1218-1229.
81. Han C.H., Freeman J.L., Lee T., et al. Regulation of the neutrophil respiratory burst oxidase. Identification of an activation domain in p67(phox). J. Biol. Chem. 1998, 273:16663-16668.
82. Dang P.M., Cross A.R., Babior B.M. Assembly of the neutrophil respiratory burst oxidase: a direct interaction between p67PHOX and cytochrome b558. Proc. Natl. Acad. Sci. USA 2001, 98:3001-3005.
83. Gorlach A., Lee P.L., Roesler J., et al. A p47-phox pseudogene carries the most common mutation causing p47-phox- deficient chronic granulomatous disease. J. Clin. Investig. 1997, 100:1907-1918.
84. Vazquez N., Lehrnbecher T., Chen R., et al. Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: the significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes. Exp. Hematol. 2001, 29:234-243.
85. Heyworth P.G., Noack D., Cross A.R. Identification of a novel NCF-1 (p47-phox) pseudogene not containing the signature GT deletion: significance for A47 degrees chronic granulomatous disease carrier detection. Blood 2002, 100:1845-1851.
86. Hayrapetyan A., Dencher P.C., van Leeuwen K., et al. Different unequal cross-over events between NCF1 and its pseudogenes in autosomal p47(phox)-deficient chronic granulomatous disease. Biochim. Biophys. Acta 2013, 1832:1662-1672.
87. Brunson T., Wang Q., Chambers I., et al. A copy number variation in human NCF1 and its pseudogenes. BMC Genet. 2010, 11:13.
88. Olsson L.M., Nerstedt A., Lindqvist A.K., et al. Copy number variation of the gene NCF1 is associated with rheumatoid arthritis. Antioxid. Redox Signal. 2012, 16:71-78.
89. Kabuki T., Kawai T., Kin Y., et al. A case of Williams syndrome with p47-phox-deficient chronic granulomatous disease. Nihon Rinsho Meneki Gakkai Kaishi 2003, 26:299-303.
90. Gilbert-Barness E., Fox T., Morrow G., et al. Williams syndrome associated with Crohn disease, multiple infections, and chronic granulomatous disease. Fetal Pediatr. Pathol. 2004, 23:29-37.
91. Del Campo M., Antonell A., Magano L.F., et al. Hemizygosity at the NCF1 gene in patients with Williams-Beuren syndrome decreases their risk of hypertension. Am. J. Hum. Genet. 2006, 78:533-542.
92. Stasia M.J., Mollin M., Martel C., et al. Functional and genetic characterization of two extremely rare cases of Williams-Beuren syndrome associated with chronic granulomatous disease. Eur. J. Hum. Genet. 2013, 21:1079-1084.
93. Stasia M.J., Li X.J. Genetics and immunopathology of chronic granulomatous disease. Semin. Immunopathol. 2008, 30:209-235.
94. Roesler J., Segerer F., Morbach H., et al. P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD). PLoS ONE 2012, 7:e34296.
95. Roos D., van Buul J.D., Tool A.T.J., et al. Two CGD families with a hypomorphic mutation in the activation domain of p67phox. J. Clin. Cell. Immunol. 2014, 5:1-8.
96. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
97. Yu J., Vodyanik M.A., Smuga-Otto K., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
98. Inoue H., Nagata N., Kurokawa H., et al. iPS cells: a game changer for future medicine. EMBO J. 2014, 33:409-417.
99. Singh V.K., Kalsan M., Kumar N., et al. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front. Cell. Dev. Biol. 2015, 3:2.
100. Mukherjee S., Santilli G., Blundell M.P., et al. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS ONE 2011, 6:e17565.
101. Santilli G., Almarza E., Brendel C., et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther. 2011, 19:122-132.
102. Zou J., Sweeney C.L., Chou B.K., et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011, 117:5561-5572.
103. Sweeney C.L., Merling R.K., Choi U., et al. Generation of functionally mature neutrophils from induced pluripotent stem cells. Methods Mol. Biol. 2014, 1124:189-206.
104. Yokoyama Y., Suzuki T., Sakata-Yanagimoto M., et al. Derivation of functional mature neutrophils from human embryonic stem cells. Blood 2009, 113:6584-6592.
105. Hockemeyer D., Soldner F., Beard C., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 2009, 27:851-857.
106. Jiang Y., Cowley S.A., Siler U., et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells 2012, 30:599-611.
107. Brault J., Goutagny E., Telugu N., et al. Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells: ex vivo models of X(0)-linked, AR22(0)- and AR47(0) - chronic granulomatous diseases. Biores. Open Access 2014, 3:311-326.
108. Choi K.D., Vodyanik M.A., Slukvin I.I. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J. Clin. Investig. 2009, 119:2818-2829.
109. Choi K.D., Vodyanik M., Slukvin I.I. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat. Protoc. 2011, 6:296-313.
110. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
111. Biasi F., Leonarduzzi G., Oteiza P.I., et al. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid. Redox Signal. 2013, 19:1711-1747.
112. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(46-54):e42.
113. Benchimol E.I., Mack D.R., Nguyen G.C., et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014, 147:803-813 e7. quiz e14-5.
114. Hope B., Shahdadpuri R., Dunne C., et al. Rapid rise in incidence of Irish paediatric inflammatory bowel disease. Arch. Dis. Child. 2012, 97:590-594.
115. Eszter Muller K., Laszlo Lakatos P., Papp M., et al. Incidence and paris classification of pediatric inflammatory bowel disease. Gastroenterol. Res. Pract. 2014, 2014:904307.
116. Uhlig H.H., Schwerd T., Koletzko S., et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014, 147(990-1007):e3.
117. Gevers D., Kugathasan S., Denson L.A., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014, 15:382-392.
118. Haberman Y., Tickle T.L., Dexheimer P.J., et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Investig. 2014, 124:3617-3633.
119. Marciano B.E., Rosenzweig S.D., Kleiner D.E., et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004, 114:462-468.
120. Alimchandani M., Lai J.P., Aung P.P., et al. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am. J. Surg. Pathol. 2013, 37:1365-1372.
121. Barbato M., Ragusa G., Civitelli F., et al. Chronic granulomatous disease mimicking early-onset Crohn's disease with cutaneous manifestations. BMC Pediatr. 2014, 14:156.
122. Muise A.M., Walters T., Xu W., et al. Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. Gastroenterology 2011, 141:633-641.
123. Muise A.M., Snapper S.B., Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology 2012, 143:285-288.
124. Dhillon S.S., Fattouh R., Elkadri A., et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology 2014, 147(680-689):e2.
125. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275:3249-3277.
126. Roberts R.L., Hollis-Moffatt J.E., Gearry R.B., et al. Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes Immun. 2008, 9:561-565.
127. Rioux J.D., Xavier R.J., Taylor K.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 2007, 39:596-604.
128. Somasundaram R., Deuring J.J., van der Woude C.J., et al. Linking risk conferring mutations in NCF4 to functional consequences in Crohn's disease. Gut 2012, 61:1097. author reply 1097-1098.
129. Dang P.M., Elbim C., Marie J.C., et al. Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity. FASEB J. 2006, 20:1504-1506.
130. Glas J., Seiderer J., Pasciuto G., et al. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. Am. J. Gastroenterol. 2009, 104:665-672.
131. Amre D.K., Mack D.R., Israel D., et al. NELL1, NCF4, and FAM92B genes are not major susceptibility genes for Crohn's disease in Canadian children and young adults. Inflamm. Bowel Dis. 2012, 18:529-535.
132. Dhillon S.S., Mastropaolo L.A., Murchie R., et al. Higher activity of the inducible nitric oxide synthase contributes to very early onset inflammatory bowel disease. Clin. Transl. Gastroenterol. 2014, 5:e46.
133. Selemidis S., Dusting G.J., Peshavariya H., et al. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc. Res. 2007, 75:349-358.
134. Hornsby M.J., Huff J.L., Kays R.J., et al. Helicobacter pylori induces an antimicrobial response in rhesus macaques in a cag pathogenicity island-dependent manner. Gastroenterology 2008, 134:1049-1057.
135. Aerssens J., Camilleri M., Talloen W., et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2008, 6:194-205.
136. Strengert M., Jennings R., Davanture S., et al. Mucosal reactive oxygen species are required for antiviral response: role of Duox in influenza a virus infection. Antioxid. Redox Signal. 2014, 20:2695-2709.
137. Grasberger H., El-Zaatari M., Dang D.T., et al. Dual oxidases control release of hydrogen peroxide by the gastric epithelium to prevent Helicobacter felis infection and inflammation in mice. Gastroenterology 2013, 145:1045-1054.
138. Hayes P., Dhillon S., O'Neill K., et al. Defects in NADPH oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease. Cell. Mol. Gastroenterol. Hepatol. 2015, in press.
139. Corcionivoschi N., Alvarez L.A., Sharp T.H., et al. Mucosal reactive oxygen species decrease virulence by disrupting campylobacter jejuni phosphotyrosine signaling. Cell Host Microbe 2012, 12:47-59.
140. Bao S., Carr E.D., Xu Y.H., et al. Gp91(phox) contributes to the development of experimental inflammatory bowel disease. Immunol. Cell. Biol. 2011, 89:853-860.
141. Krieglstein C.F., Cerwinka W.H., Laroux F.S., et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J. Exp. Med. 2001, 194:1207-1218.
142. Rodrigues-Sousa T., Ladeirinha A.F., Santiago A.R., et al. Deficient production of reactive oxygen species leads to severe chronic DSS-induced colitis in Ncf1/p47phox-mutant mice. PLoS ONE 2014, 9:e97532.
143. Campbell E.L., Bruyninckx W.J., Kelly C.J., et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 2014, 40:66-77.
144. Conway K.L., Goel G., Sokol H., et al. p40phox expression regulates neutrophil recruitment and function during the resolution phase of intestinal inflammation. J. Immunol. 2012, 189:3631-3640.
145. Leoni G., Alam A., Neumann P.A., et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J. Clin. Investig. 2013, 123:443-454.
146. Treton X., Pedruzzi E., Guichard C., et al. Combined NADPH oxidase 1 and interleukin 10 deficiency induces chronic endoplasmic reticulum stress and causes ulcerative colitis-like disease in mice. PLoS ONE 2014, 9:e101669.
147. Lipinski S., Till A., Sina C., et al. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J. Cell Sci. 2009, 122:3522-3530.
148. MacFie T.S., Poulsom R., Parker A., et al. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm. Bowel Dis. 2014, 20:514-524.
149. Lee P.P., Chan K.W., Jiang L., et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr. Infect. Dis. J. 2008, 27:224-230.
150. Barese C., Copelli S., Zandomeni R., et al. X-linked chronic granulomatous disease: first report of mutations in patients of Argentina. J. Pediatr. Hematol. Oncol. 2004, 26:656-660.
151. Naidoo R., Jordaan N., Chan K.W., et al. A novel CYBB mutation with the first genetically confirmed case of chronic granulomatous disease in South Africa. S. Afr. Med. J. 2011, 101:768-769.
152. Bustamante J., Arias A.A., Vogt G., et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat. Immunol. 2011, 12:213-221.
153. Zalba G., San Jose G., Beaumont F.J., et al. Polymorphisms and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ. Res. 2001, 88:217-222.
154. Olofsson P., Holmberg J., Tordsson J., et al. Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat. Genet. 2003, 33:25-32.
155. Hultqvist M., Olofsson P., Holmberg J., et al. Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. Proc. Natl. Acad. Sci. USA 2004, 101:12646-12651.
156. Hagenow K., Gelderman K.A., Hultqvist M., et al. Ncf1-associated reduced oxidative burst promotes IL-33R+ T cell-mediated adjuvant-free arthritis in mice. J. Immunol. 2009, 183:874-881.
157. Hultqvist M., Olofsson P., Gelderman K.A., et al. A new arthritis therapy with oxidative burst inducers. PLoS Med. 2006, 3:e348.
158. Jacob C.O., Eisenstein M., Dinauer M.C., et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc. Natl. Acad. Sci. USA 2012, 109:E59-E67.
159. Kim-Howard X., Sun C., Molineros J.E., et al. Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum. Mol. Genet. 2014, 23:1656-1668.
160. Cunninghame Graham D.S., Morris D.L., Bhangale T.R., et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011, 7:e1002341.
161. Campbell A.M., Kashgarian M., Shlomchik M.J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 2012, 4:157ra141.
162. Toublanc J.E. Comparison of epidemiological data on congenital hypothyroidism in Europe with those of other parts in the world. Horm. Res. 1992, 38:230-235.
163. De Felice M., Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr. Rev. 2004, 25:722-746.
164. De Deken X., Wang D., Many M.C., et al. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J. Biol. Chem. 2000, 275:23227-23233.
165. Royaux I.E., Suzuki K., Mori A., et al. Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology 2000, 141:839-845.
166. Yoshida A., Taniguchi S., Hisatome I., et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J. Clin. Endocrinol. Metab. 2002, 87:3356-3361.
167. Twyffels L., Strickaert A., Virreira M., et al. Anoctamin-1/TMEM16A is the major apical iodide channel of the thyrocyte. Am. J. Physiol. Cell Physiol. 2014, 307:C1102-C1112.
168. Ieiri T., Cochaux P., Targovnik H.M., et al. A 3' splice site mutation in the thyroglobulin gene responsible for congenital goiter with hypothyroidism. J. Clin. Investig. 1991, 88:1901-1905.
169. Cangul H., Boelaert K., Dogan M., et al. Novel truncating thyroglobulin gene mutations associated with congenital hypothyroidism. Endocrine 2014, 45:206-212.
170. Cangul H., Darendeliler F., Saglam Y., et al. A truncating TPO mutation (Y55X) in patients with hypothyroidism and total iodide organification defect. Endocr. Res. 2015, 40:146-150.
171. Bikker H., den Hartog M.T., Baas F., et al. A 20-basepair duplication in the human thyroid peroxidase gene results in a total iodide organification defect and congenital hypothyroidism. J. Clin. Endocrinol. Metab. 1994, 79:248-252.
172. Abramowicz M.J., Targovnik H.M., Varela V., et al. Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. J. Clin. Investig. 1992, 90:1200-1204.
173. Fujiwara H., Tatsumi K., Miki K., et al. Congenital hypothyroidism caused by a mutation in the Na+/I- symporter. Nat. Genet. 1997, 16:124-125.
174. Pohlenz J., Medeiros-Neto G., Gross J.L., et al. Hypothyroidism in a Brazilian kindred due to iodide trapping defect caused by a homozygous mutation in the sodium/iodide symporter gene. Biochem. Biophys. Res. Commun. 1997, 240:488-491.
175. Pohlenz J., Rosenthal I.M., Weiss R.E., et al. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. Identification of a nonsense mutation producing a downstream cryptic 3' splice site. J. Clin. Investig. 1998, 101:1028-1035.
176. Everett L.A., Glaser B., Beck J.C., et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat. Genet. 1997, 17:411-422.
177. Bogazzi F., Raggi F., Ultimieri F., et al. A novel mutation in the pendrin gene associated with Pendred's syndrome. Clin. Endocrinol. 2000, 52:279-285.
178. Moreno J.C., Klootwijk W., van Toor H., et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N. Engl. J. Med. 2008, 358:1811-1818.
179. Afink G., Kulik W., Overmars H., et al. Molecular characterization of iodotyrosine dehalogenase deficiency in patients with hypothyroidism. J. Clin. Endocrinol. Metab. 2008, 93:4894-4901.
180. Moreno J.C., Bikker H., Kempers M.J., et al. Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N. Engl. J. Med. 2002, 347:95-102.
181. Vigone M.C., Fugazzola L., Zamproni I., et al. Persistent mild hypothyroidism associated with novel sequence variants of the DUOX2 gene in two siblings. Hum. Mutat. 2005, 26:395.
182. Varela V., Rivolta C.M., Esperante S.A., et al. Three mutations (p.Q36H, p.G418fsX482, and g.IVS19-2A>C) in the dual oxidase 2 gene responsible for congenital goiter and iodide organification defect. Clin. Chem. 2006, 52:182-191.
183. Pfarr N., Musholt T.J., Musholt P.B., et al. Congenital primary hypothyroidism with subsequent adenomatous goiter in a Turkish patient caused by a homozygous 10-bp deletion in the thyroid peroxidase (TPO) gene. Clin. Endocrinol. 2006, 64:514-518.
184. Ohye H., Fukata S., Hishinuma A., et al. A novel homozygous missense mutation of the dual oxidase 2 (DUOX2) gene in an adult patient with large goiter. Thyroid 2008, 18:561-566.
185. Maruo Y., Takahashi H., Soeda I., et al. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J. Clin. Endocrinol. Metab. 2008, 93:4261-4267.
186. Tonacchera M., De Marco G., Agretti P., et al. Identification and functional studies of two new dual-oxidase 2 (DUOX2) mutations in a child with congenital hypothyroidism and a eutopic normal-size thyroid gland. J. Clin. Endocrinol. Metab. 2009, 94:4309-4314.
187. Hoste C., Rigutto S., Van Vliet G., et al. Compound heterozygosity for a novel hemizygous missense mutation and a partial deletion affecting the catalytic core of the H2O2-generating enzyme DUOX2 associated with transient congenital hypothyroidism. Hum. Mutat. 2010, 31:E1304-E1319.
188. De Marco G., Agretti P., Montanelli L., et al. Identification and functional analysis of novel dual oxidase 2 (DUOX2) mutations in children with congenital or subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 2011, 96:E1335-E1339.
189. Narumi S., Muroya K., Asakura Y., et al. Molecular basis of thyroid dyshormonogenesis: genetic screening in population-based Japanese patients. J. Clin. Endocrinol. Metab. 2011, 96:E1838-E1842.
190. Kasahara T., Narumi S., Okasora K., et al. Delayed onset congenital hypothyroidism in a patient with DUOX2 mutations and maternal iodine excess. Am. J. Med. Genet. A 2013, 161A:214-217.
191. Yoshizawa-Ogasawara A., Ogikubo S., Satoh M., et al. Congenital hypothyroidism caused by a novel mutation of the dual oxidase 2 (DUOX2) gene. J. Pediatr. Endocrinol. Metab. 2013, 26:45-52.
192. Cangul H., Aycan Z., Kendall M., et al. A truncating DUOX2 mutation (R434X) causes severe congenital hypothyroidism. J. Pediatr. Endocrinol. Metab. 2014, 27:323-327.
193. Wang F., Lu K., Yang Z., et al. Genotypes and phenotypes of congenital goitre and hypothyroidism caused by mutations in dual oxidase 2 genes. Clin. Endocrinol. 2014, 81:452-457.
194. Jin H.Y., Heo S.H., Kim Y.M., et al. High frequency of DUOX2 mutations in transient or permanent congenital hypothyroidism with eutopic thyroid glands. Horm. Res. Paediatr. 2014, 82:252-260.
195. Abe K., Narumi S., Suwanai A.S., et al. Pseudodominant inheritance in a family with nonautoimmune hypothyroidism due to biallelic DUOX2 mutations. Clin. Endocrinol. 2014.
196. Satoh M., Aso K., Ogikubo S., et al. Hypothyroidism caused by the combination of two heterozygous mutations: one in the TSH receptor gene the other in the DUOX2 gene. J. Pediatr. Endocrinol. Metab. 2015, 28:657-661.
197. Yi R.H., Zhu W.B., Yang L.Y., et al. A novel dual oxidase maturation factor 2 gene mutation for congenital hypothyroidism. Int. J. Mol. Med. 2013, 31:467-470.
198. Liu S., Liu L., Niu X., et al. A novel missense mutation (I26M) in DUOXA2 causing congenital goiter hypothyroidism impairs NADPH oxidase activity but not protein expression. J. Clin. Endocrinol. Metab. 100, 2015, 1225-1229, jc20143964.
199. Hulur I., Hermanns P., Nestoris C., et al. A single copy of the recently identified dual oxidase maturation factor (DUOXA) 1 gene produces only mild transient hypothyroidism in a patient with a novel biallelic DUOXA2 mutation and monoallelic DUOXA1 deletion. J. Clin. Endocrinol. Metab. 2011, 96:E841-E845.
200. Zamproni I., Grasberger H., Cortinovis F., et al. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J. Clin. Endocrinol. Metab. 2008, 93:605-610.
201. Park S.M., Chatterjee V.K. Genetics of congenital hypothyroidism. J. Med. Genet. 2005, 42:379-389.
202. Dupuy C., Ohayon R., Valent A., et al. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cdnas. J. Biol. Chem. 1999, 274:37265-37269.
203. Geiszt M., Witta J., Baffi J., et al. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 2003, 17:1502-1504.
204. Forteza R., Salathe M., Miot F., et al. Regulated hydrogen peroxide production by Duox in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2005, 32:462-469.
205. Harper R.W., Xu C., Eiserich J.P., et al. Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett. 2005, 579:4911-4917.
206. El Hassani R.A., Benfares N., Caillou B., et al. Dual oxidase2 is expressed all along the digestive tract. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G933-G942.
207. Fletcher N.M., Saed M.G., Abuanzeh S., et al. Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod. Sci. 2014, 21:1145-1152.
208. Choi H., Park J.Y., Kim H.J., et al. Hydrogen peroxide generated by DUOX1 regulates the expression levels of specific differentiation markers in normal human keratinocytes. J. Dermatol. Sci. 2014, 74:56-63.
209. Song Y., Ruf J., Lothaire P., et al. Association of duoxes with thyroid peroxidase and its regulation in thyrocytes. J. Clin. Endocrinol. Metab. 2010, 95:375-382.
210. Corvilain B., Collyn L., van Sande J., et al. Stimulation by iodide of H(2)O(2) generation in thyroid slices from several species. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E692-E699.
211. Cardoso L.C., Martins D.C., Figueiredo M.D., et al. Ca(2+)/nicotinamide adenine dinucleotide phosphate-dependent H(2)O(2) generation is inhibited by iodide in human thyroids. J. Clin. Endocrinol. Metab. 2001, 86:4339-4343.
212. Song Y., Driessens N., Costa M., et al. Roles of hydrogen peroxide in thyroid physiology and disease. J. Clin. Endocrinol. Metab. 2007, 92:3764-3773.
213. Edens W.A., Sharling L., Cheng G., et al. Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phox. J. Cell. Biol. 2001, 154:879-891.
214. Daiyasu H., Toh H. Molecular evolution of the myeloperoxidase family. J. Mol. Evol. 2000, 51:433-445.
215. Donko A., Peterfi Z., Sum A., et al. Dual oxidases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360:2301-2308.
216. Meitzler J.L., Ortiz de Montellano P.R. Caenorhabditis elegans and human dual oxidase 1 (DUOX1) "peroxidase" domains: insights into heme binding and catalytic activity. J. Biol. Chem. 2009, 284:18634-18643.
217. Pociot F., Lorenzen T., Nerup J. A manganese superoxide dismutase (SOD2) gene polymorphism in insulin-dependent diabetes mellitus. Dis. Markers 1993, 11:267-274.
218. Zelko I.N., Mariani T.J., Folz R.J. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002, 33:337-349.
219. Harper R.W., Xu C., McManus M., et al. Duox2 exhibits potent heme peroxidase activity in human respiratory tract epithelium. FEBS Lett. 2006, 580:5150-5154.
220. Rigutto S., Hoste C., Grasberger H., et al. Activation of dual oxidases Duox1 and Duox2: differential regulation mediated by camp-dependent protein kinase and protein kinase C-dependent phosphorylation. J. Biol. Chem. 2009, 284:6725-6734.
221. Hill T., Xu C., Harper R.W. IFNgamma mediates DUOX2 expression via a STAT-independent signaling pathway. Biochem. Biophys. Res. Commun. 2010, 395:270-274.
222. Grandvaux N., Mariani M., Fink K. Lung epithelial NOX/DUOX and respiratory virus infections. Clin. Sci. 2015, 128:337-347.
223. Meitzler J.L., Ortiz de Montellano P.R. Structural stability and heme binding potential of the truncated human dual oxidase 2 (DUOX2) peroxidase domain. Arch. Biochem. Biophys. 2011, 512:197-203.
224. De Deken X., Wang D., Dumont J.E., et al. Characterization of ThOX proteins as components of the thyroid H(2)O(2)-generating system. Exp. Cell Res. 2002, 273:187-196.
225. Grasberger H., Refetoff S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. J. Biol. Chem. 2006, 281:18269-18272.
226. Luxen S., Belinsky S.A., Knaus U.G. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 2008, 68:1037-1045.
227. Luxen S., Noack D., Frausto M., et al. Heterodimerization controls localization of Duox-DuoxA NADPH oxidases in airway cells. J. Cell Sci. 2009, 122:1238-1247.
228. Ameziane-El-Hassani R., Talbot M., de Souza Dos Santos M.C., et al. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc. Natl. Acad. Sci. USA 2015, 112:5051-5056.
229. Morand S., Ueyama T., Tsujibe S., et al. Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation. FASEB J. 2009, 23:1205-1218.
230. Hoste C., Dumont J.E., Miot F., et al. The type of DUOX-dependent ROS production is dictated by defined sequences in DUOXA. Exp. Cell. Res. 2012, 318:2353-2364.
231. Ueyama T., Sakuma M., Ninoyu Y., et al. The extracellular A-loop of dual oxidases affects the specificity of reactive oxygen species release. J. Biol. Chem. 2015, 290:6495-6506.
232. Morand S., Agnandji D., Noel-Hudson M.S., et al. Targeting of the dual oxidase 2N-terminal region to the plasma membrane. J. Biol. Chem. 2004, 279:30244-30251.
233. 2-generating activity. J. Biol. Chem. 2005, 280:30046-30054.
234. Meitzler J.L., Hinde S., Banfi B., et al. Conserved cysteine residues provide a protein-protein interaction surface in dual oxidase (DUOX) proteins. J. Biol. Chem. 2013, 288:7147-7157.
235. Carre A., Louzada R.A., Fortunato R.S., et al. When an intramolecular disulfide bridge governs the interaction of DUOX2 with its partner DUOXA2. Antioxid. Redox Signal. 2015.
236. Donko A., Morand S., Korzeniowska A., et al. Hypothyroidism-associated missense mutation impairs NADPH oxidase activity and intracellular trafficking of Duox2. Free Radic. Biol. Med. 2014, 73:190-200.
237. Grasberger H., De Deken X., Mayo O.B., et al. Mice deficient in dual oxidase maturation factors are severely hypothyroid. Mol. Endocrinol. 2012, 26:481-492.
238. Johnson K.R., Marden C.C., Ward-Bailey P., et al. Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2. Mol. Endocrinol. 2007, 21:1593-1602.
239. Donko A., Ruisanchez E., Orient A., et al. Urothelial cells produce hydrogen peroxide through the activation of Duox1. Free Radic. Biol. Med. 2010, 49:2040-2048.
240. Ishikawa K., Takenaga K., Akimoto M., et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664.
241. Iommarini L., Kurelac I., Capristo M., et al. Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. Hum. Mol. Genet. 2014, 23:1453-1466.
242. El-Sohemy A., Cornelis M.C., Park Y.W., et al. Catalase and PPARgamma2 genotype and risk of rheumatoid arthritis in Koreans. Rheumatol. Int. 2006, 26:388-392.
243. Bohanec Grabar P., Logar D., Tomsic M., et al. Genetic polymorphisms modifying oxidative stress are associated with disease activity in rheumatoid arthritis patients. Dis. Markers 2009, 26:41-48.
244. Khodayari S., Salehi Z., Fakhrieh Asl S., et al. Catalase gene C-262T polymorphism: importance in ulcerative colitis. J. Gastroenterol. Hepatol. 2013, 28:819-822.
245. Matus S., Valenzuela V., Medinas D.B., et al. ER dysfunction and protein folding stress in ALS. Int. J. Cell Biol. 2013, 2013:674751.
246. Prudencio M., Borchelt D.R. Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states. Mol. Neurodegener. 2011, 6:77.
247. Stasia M.J., Bordigoni P., Martel C., et al. A novel and unusual case of chronic granulomatous disease in a child with a homozygous 36-bp deletion in the CYBA gene (A22(0)) leading to the activation of a cryptic splice site in intron 4. Hum. Genet. 2002, 110:444-450.